MBL History

2009

• Apr.:Launched new product ; Ribocluster profiler™ RIP-Assay Kit (A kit for the isolation and purification of only functionally related messenger RNA (mRNA) inside the cell ) and RIP-Certified Antibody series (A series of antibodies capable of immunoprecipitating the complex formed by mRNA and RNA-binding proteins (RBP))
• Apr.:Launched new product ; TACAS™ system (A new system of liquid based cytology to detect early stage of cervical cancer that includes sampling into preservative fluid, automated preparation with high speed)

2008

• July: MBL International Corporation purchased BION Enterprises (USA)
• Jun.:Launched new product ; Fucci (Fluorescent Ubiquitination-based Cell Cycle Indicator), which is produced by Amalgaam Co., Ltd, is a sophisticated technology of real time cell cycle analysis in living cells. Concluded collaborative research agreement with Kyoto Univ. for antibody drug discovery targeting regulatory T cell
• Apr.:Satoshi Karasawa : Head of Technology Development div. of Amalgaam Co., Ltd. honored by the Ministry of Education, Culture, Sports, Science and Technology for technology award
• Mar.:Concluded collaborative research agreement with Kyoto Univ. for antibody drug discovery targeting regulatory T cell
• Feb.:Launched new product ; CoralHue® improved orange fluorescence protein vector (Kusabira-Orange2)
• Jan.:Launched HLA DNA typing kit " Genosearch HLA-DRB1 Ver.2"

2007

• Dec.:Launched new product ; CoralHue® vector set (FRET set)
• Dec.:Launched new product ; T-Select Human CD1d Tetramer
• Nov.: Launched EIA AMH/MIS ; ELISA assay for human serum and plasma Mullerian-Inhibiting Factor (AMH/MIS)
• Nov.: Founded "JMSeed Bio Incubation the 1st. investment business limited liability association "
• Aug.: Launched MESACUP® anti-p53 test ; diagnostic reagent enabling early diagnosis for esophagus cancer, colon cancer, breast cancer
• Aug.: Launched new product; regulatory T cell marker antibody anti-Foxp3
• May:Concluded distribution agreement with Roche (Diagnostic Division) for quantitative reagents for factor XIII and its launch.
• Mar.: Launched new product ; reagent for detecting EB virus antibody (In vitro diagnostics)
• Feb.:Launched T-Select WT1 Tetramer reagent for detecting CTL which recognizes cancer antigen WT1
• Jan.:Launched MESACUP® CCP test as diagnostic reagent for rheumatoid arthritis

2006

MBL International Corporation purchased antibody business of LifeSpan BioSciences (USA).
Financing to PrevenTec, Inc., engaged in preventing infectious diseases, allergy diseases and developing new method of using antibodies for treatment through technologies of producing a large amount of antibodies with rice plant.
Concluded exclusive distribution agreement with Immunodiagnostics Systems (UK) for assay reagents for bone metabolism.
Concluded distribution agreement with Cylex Inc.(USA) for immune cell activation assay reagents.
ISO13485 accredited.p

2005

Merger of Genome Science Laboratories and AdGene , then changed name to G ＆ G Science Co., Ltd.
Merger of MBL International Corporation and RhiGene Inc. and continues as MBL International Corporation.
Established a joint venture company with DNAVEC in Beijing, Beijing B ＆ M Biotech Co., Ltd.
Concluded distribution agreement with Roche Diagnostics for gene type determination kit for human papilloma virus(HPV).
Financing to ACTGen Co., Ltd.,engaged in making antibodies and developing antibody drug utilizing virus vector technology.
Financing to Oncomics Co., Ltd., engaged in research and development for method for predicting clinical disease stage and for molecular targeting drug for intractable cancer.
Financing to BioMedCore Inc., engaged in developing cell therapy and immunological treatment.

2004

Established a limited company GEL-Design (now GEL – Design Co., Ltd. ) as raw materials development company based on technologies of functional high molecular raw material especially jelly-like raw material originating from Hokkaido University.
Concluded business tie-up with DNAVEC Corporation for Sendai virus vector.

2003

Established a limited company: Amalgaam Co., Ltd. for research and development for novel fluorescent protein.
Concluded sublicensing agreement with Diagnostic Products Corporation (now Siemens) granting them license for Duke Univ. patents MBL possesses.
Concluded collaborative research agreement with Oncotherapy Science, Institute for Antibodies for developing antibody drug which targets cancer.
Financing to Chromo Research Co.,Ltd., engaging in research and development for artificial chromosome.
Started synthesic oligo making business for Integrated DNA Technologies Inc.(USA): nucleic acid synthesis making maker.
Concluded collaboration research agreement with Okayama University for new diagnostic reagents for arteriosclerosis.
License granted from TOYOTA CENTRAL R ＆ D LABS. , INC. for technology and patent for stress level assessment using saliva chromogranin.
Announcement for concluding collaboration research agreement among Institute for Antibodies, MBL, and Oncotherapy, in reference to development of antibodies for therapeutics
Support of founding NPO BIO Factory Central JAPAN.
Formed a capital tie-up with Summit Glyco Research Co., Ltd.

2002

Concluded Agreement with Keio University School of Medicine for collaborative research and permission to use research park.
Concluded strategic cooperation with Beckman Coulter (USA) for MHC tetramer technology for T cell analysis.
Concluded distribution agreement with Corgenix, granting them to distribute MBL diagnostic products in USA and Europe.
Worldwide exclusive license granted from Oncotherapy Science and allowed to utilize research achievements obtained from human cancer specific gene products to reagents for research and diagnostic reagents medical supply.　　

2001

Financing to Ginkgo Biomedical Research Institute Co., Ltd. (now SBI Biotech Co., Ltd.). Financing to Ribonomics Inc. (USA).

2000

Out-license Duke Univ. patent granted to MBL, to Roche.
Established MBL Venture Capital Co., Ltd. (Life Science Investment Business Association) engaged in support investment toward establishing bioventure companies.
Financing to research and development company : Protein Wave Corporation in reference to protein structure analysis technology.

1999

Distribution agreement with RDKK (Roche Diagnostics).
Established Institute for Antibodies Co.,Ltd. for research of manufacturing technologies of antibodies utilizing Phage antibody library.
Established Genome Science Laboratories Co.,Ltd. ( made as a result of acquiring and succeeding to Sumitomo Metal Industries‘s Ltd. Diagnostic Division).
ISO9002 accredited.

1998

Concluded exclusive (Japan) distribution agreement with TriPath Imaging (now BD, Becton Dickinson and Company) (USA) for automatic-device for cytological smear and its specific equipment and reagents .
Concluded Agreement with Hayashibara Biochemical Labs. Inc. and worldwide exclusive license granted for commercializing a series of technology including domestic and foreign patents, know-how for IL-18 (Interferon γ production inducing factor) to diagnostic reagents and reagents for research.
Established in Ina, Nagano, CycLex Co., Ltd. as research ＆ development bioventure.
Established in Illinois USA, a subsidiary : RhiGene Inc. for manufacturing and distribution for autoimmune diseases testing reagents.
Concluded exclusive (Japan) distribution Agreement with Roche Diagnostics KK for test reagents for systemic autoimmune diseases for Cobas Core II.

1997

Started establishment of ‘MBL-Network’affiliated companies and is investing other domestic bio-venture companies.

1996

Listed on JASDAQ (Jasdaq Securities Exchange, Inc.).Worldwide distribution license granted from BioWhittaker (USA) for MESACUP ENA test series utilizing gene recombinant technology.

1994

Concluded exclusive (Japan) distribution agreement with Equitech Bio (USA) for fetal bovine serum.

1993

Established its first overseas subsidiary “MBL International Corporation”in Boston, USA.
The 1st Autoimmunity and Autoantibodies Symposium was held ( every year ever since ).

1992

Launched ”Anti-human Fas monoclonal antibody”which induces apoptosis.

1991

Development of reagents for measuring autoantibodies with recombinant DNA technology“MESACUP ENA test series”

1990

In-License of DNA recombination technology from Duke Univ.

1989

Tie-up with IMMUNOTECH S.A. in France (now Beckman-Coulter company) and introduced many Cell biological reagents.
The first“Takato symposium on molecular cell biology”was held (every year ever since ).

1987

Focusing on development of research reagents for cell biology.

1985

Development of a test reagent for antinuclear antibody based on immunofluorescence method“Fluoro HEPANA test”.

1983

Established in-house system of R＆D, manufacturing and distribution.
Starting development of monoclonal antibodies by cell fusion.
Survey of autoantibodies was reported (every year ever since).

1979

Ina laboratory opened in Nagano prefecture.

1977

Starting development of diagnostic reagents for autoimmune diseases.

1976

Development of “EIA IgE test”, the first test reagent in the world for allergy using EIA method.

1975

Success in manufacturing of immunodiffusion plate for plasma proteins (“MBL Plate”) and initial marketing alliance.

1969

Established as an antibody maker in Nagoya, Japan.